Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S.

Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2.

2.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

3.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
4.

A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.

Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR.

Pharmacoeconomics. 2013 Jul;31(7):589-604. doi: 10.1007/s40273-013-0035-8.

5.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV.

Thromb Haemost. 2012 Oct;108(4):672-82. Epub 2012 Aug 17.

PMID:
22898892
6.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM.

Thromb Haemost. 2011 May;105(5):908-19. doi: 10.1160/TH11-02-0089. Epub 2011 Mar 22.

PMID:
21431243
7.

Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.

Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP.

S Afr Med J. 2013 Feb 15;103(4):241-5. doi: 10.7196/samj.6471.

PMID:
23547700
8.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
9.

Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.

Singh SM, Micieli A, Wijeysundera HC.

Circulation. 2013 Jun 18;127(24):2414-23. doi: 10.1161/CIRCULATIONAHA.112.000920. Epub 2013 May 22.

10.

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

Langkilde LK, Bergholdt Asmussen M, Overgaard M.

J Med Econ. 2012;15(4):695-703. doi: 10.3111/13696998.2012.673525. Epub 2012 Mar 22.

PMID:
22397590
11.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.

Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.

12.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
13.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.

Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2013 May;36(5):280-5. doi: 10.1002/clc.22112. Epub 2013 Mar 14.

14.
15.

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

J Med Econ. 2012;15(4):776-85. doi: 10.3111/13696998.2012.680555. Epub 2012 Apr 13.

PMID:
22449118
16.

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.

Davidson T, Husberg M, Janzon M, Oldgren J, Levin LÅ.

Eur Heart J. 2013 Jan;34(3):177-83. doi: 10.1093/eurheartj/ehs157. Epub 2012 Jun 24.

PMID:
22733833
17.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

18.

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.

Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2013 Jul;31(7):551-62. doi: 10.1007/s40273-013-0051-8. Review.

PMID:
23620211
19.

The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.

Amorosi SL, Armstrong S, Da Deppo L, Garfield S, Stein K.

Europace. 2014 Aug;16(8):1131-6. doi: 10.1093/europace/euu038. Epub 2014 Mar 30.

PMID:
24687964
20.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

Supplemental Content

Support Center